Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · SCHEDULE 13G/A

CryoPort, Inc.

CYRXNASDAQEQUITYCurrent

SEC Filing

Filed Jul 29, 2026Accepted Jul 29, 2026, 5:50 PM EDTCIK 1124524Accession 0001104659-26-088284
Share

Company context

Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."

Current securities

Recent company filings

  1. SCHEDULE 13G/A filingAug 14, 2026
  2. 144 filingAug 11, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. S-8 filingJun 22, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗